

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: DiNardo CD, Daver N, Jabbour E, et al. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. *Lancet Haematol* 2014; published online Dec 22. [http://dx.doi.org/10.1016/S2352-3026\(14\)00026-X](http://dx.doi.org/10.1016/S2352-3026(14)00026-X).

Supplemental Table 1:

Phase II cohort analysis

(a) univariate modeling

(b) multivariate modeling (with and without platelet count included in model)

(a)

	N	Med (wks)	p-value
Age			
<65	23	62	
>/=65	37	55	0.19
ANC			
>/=1000	23	NR	
<1000	37	55	0.28
Plt			
>/=50	25	62	
<50	35	32	0.059
Dose			
25	40	74	
>25	20	21	0.001
BM BI			
<20	36	60	
>/=20	24	55	0.35
Cyto			
Non-complex	37	62	
Complex	19	24	0.02

(b)

	Chi ² = 14.8088 df = 3 p = .00199			
	p	Risk ratio	Risk ratio 95% lower	Risk ratio 95% upper
N=56				
Plt-X	0.51	1.31	0.59	2.88
Dose-X	<0.01	2.72	1.34	5.49
CG-XX	0.02	2.53	1.14	5.64

	Chi ² = 14.3597 df = 2 p = .00076			
	p	Risk ratio	Risk ratio 95% lower	Risk ratio 95% upper
N=56				
Dose-X	<0.01	2.78	1.38	5.61
CG-XX	<0.01	2.77	1.30	5.93

Supplemental Table 2: Somatic Molecular Analysis: Coverage by gene and codon(s) tested for adequate amplicons

<u>Gene</u>	<u>Exons (codons) tested</u>
<i>ABL1</i> (NM_005157)	4-6 (243-362), 7 (395-424)
<i>AKT1</i> (NM_005163)	3 (16-49)
<i>ALK</i> (NM_004304)	23 (1172-1175), 25 (1248-1275)
<i>APC</i> (NM_000038)	16 (875-918), 16 (1113-1153), 16 (1257-1297), 16 (1288-1328), 16 (1318-1357), 16 (1349-1386), 16 (1377-1575)
<i>ATM</i> (NM_000051)	8 (353-355), 9 (409-412), 12 (601-633), 17 (846-880), 26 (1308-1331), 34 (1678-1719), 35 (1741-1773), 36 (1792-1832), 39 (1940-1973), 50 (2441-2479), 54 (2665-2670), 55 (2694-2717), 56 (2725-2756), 59 (2889-2891), 61 (2946-2950), 63 (3007-3051)
<i>BRAF</i> (NM_004333)	11 (439-471), 15 (581-606)
<i>CDH1</i> (NM_004360)	3 (77-117), 8 (369-379), 9 (399- 439)
<i>CSF1R</i> (NM_005211)	7 (297-301), 22 (926-970)
<i>CTNNB1</i> (NM_001904)	3 (12-50)
<i>DNMT3A</i> (NM_022552)	23 (866-913)
<i>EGFR</i> (NM_005228)	3 (108-142), 7 (288-297), 15 (598-627), 18-20 (708-817), 21 (857-875)
<i>ERBB2</i> (NM_004448)	19 (754-769), 20 (772-818), 21 (839-883)
<i>ERBB4</i> (NM_005235)	3 (98-140), 4 (153-186), 6 (208- 244), 7 (248-287), 8 (295-306), 9 (333-350), 15 (579-619), 23 (907-936)
<i>EZH2</i> (NM_004456)	16 (618-649)
<i>FBXW7</i> (NM_033632)	5 (243-278), 8 (375-394), 9 (429- 471), 10 (473-508), 11 (549-583)
<i>FGFR1</i> (NM_015850)	4 (120-126), 7 (247-250)
<i>FGFR2</i> (NM_000141)	7 (250-311), 7 (302-313), 9 (362- 382), 12 (521-550)
<i>FGFR3</i> (NM_000142)	7 (247-288), 9 (379-422), 14-15 (639-659), 18 (792-807)
<i>FLT3</i> (NM_004119)	11 (437-456), 14 (569-605), 16 (648-683), 20 (807-843)
<i>GNA11</i> (NM_002067)	4-5 (159-216), 6-7 (255-360)
<i>GNAQ</i> (NM_002072)	4-5 (159-245), 5-6 (241-297), 6- 7 (291-360), 7 (355-360)
<i>GNAS</i> (NM_000516)	8 (200-220)
<i>HNF1A</i> (NM_000545)	3 (205-238), 4 (271-314)
<i>HRAS</i> (NM_005343)	3 (38-63)
<i>IDH1</i> (NM_005896)	4 (90-132)
<i>IDH2</i> (NM_002168)	4 (125-178)
<i>JAK2</i> (NM_004972)	14 (615-622)
<i>JAK3</i> (NM_000215)	13 (568-573), 16 (683-723)
<i>KDR</i> (NM_002253)	6 (220-248), 7 (267-276), 11 (471-476), 19 (872-874), 21 (946-985), 26 (1135-1146), 27 (1171-1211), 30 (1308-1357)
<i>KIT</i> (NM_000222)	2 (51-93), 9-10 (502-547), 10-11 (540-592), 13 (641-664), 14 (670-712), 15 (714-745), 17 (815-828), 18 (838-866)
<i>KLHL6</i> (NM_130446)	1 (1-98)
<i>KRAS</i> (NM_004985)	2 (1-22), 3 (38-63), 4 (103-147)

<i>MET</i> (NM_001127500)	2 (168-209), 2 (375-400), 14 (1008-1028), 16 (1110-1132), 19 (1247-1284)
<i>MLH1</i> (NM_000249)	12 (383-426)
<i>MPL</i> (NM_005373)	10 (514-522)
<i>NOTCH1</i> (NM_017617)	26 (1562-1601), 27 (1673-1679)
<i>NPM1</i> (NM_002520)	11 (283-295)
<i>NRAS</i> (NM_002524)	2 (1-18), 3 (38-62)
<i>PDGFRA</i> (NM_006206)	12 (552-592), 14 (659-668), 15 (673-717), 18 (823-854)
<i>PIK3CA</i> (NM_006218)	2 (83-118), 5 (345-353), 8 (418- 445), 10 (538-555), 14 (701- 729), 21 (988-1069)
<i>PTEN</i> (NM_000314)	1 (5-27), 3 (67-70), 6 (170-210), 7 (212-266), 8 (287-342)
<i>PTPN11</i> (NM_002834)	3 (59-104), 13 (501-533)
<i>RB1</i> (NM_000321)	4 (127-158), 6 (199-203), 11 (357-376), 18 (570-605), 20 (659-700), 21 (703-733), 22 (746-775)
<i>RET</i> (NM_020975)	10-11 (610-667), 13 (766-798), 15 (880-910), 16 (918-934)
<i>SMAD4</i> (NM_005359)	3 (119-142), 5 (167-208), 6 (243- 263), 8 (310-319), 9 (329-373), 10 (385-424), 11 (443-480), 12 (496-535)
<i>SMARCB1</i> (NM_003073)	2 (39-78), 4 (156-167), 5 (199- 210), 9 (381-386)
<i>SMO</i> (NM_005631)	3 (197-242), 5 (323-366), 6 (403- 422), 9 (533-551), 11 (639-646)
<i>SRC</i> (NM_005417)	14 (530-537)
<i>STK11</i> (NM_000455)	1 (36-77), 4-5 (193-211), 6 (261- 288), 8 (332-370)
<i>TP53</i> (NM_000546)	2 (1-12), 4 (69-112), 5 (126- 186), 5-6 (181-192), 6 (187-223), 6-7 (214-253), 8 (267-306), 10 (332-342)
<i>VHL</i> (NM_000551)	2 (129-155), 3 (157-200)
<i>XPO1</i> (NM_003400)	14-15 (501-575)

Supplemental Table 3. Overview of statistical methods used to assess Kaplan-Meier survival curves

p-value test	Gr 1a	Gr 1b: Ph I vs. Ph IIb	Gr 1b: Ph I vs. Ph IIa
Gehan's Wilcoxon	0.00498	0.653	0.00022
Cox's F Test	0.00285	0.364	0.00005
Cox-Mantell	0.04305	0.783	0.00072
Peto & Peto's Wilcoxon	0.00985	0.644	0.00043
Log rank (our usual)	0.05617	0.781	0.00164

